SPECIAL REPORT
MOST SHARED
- Warren Buffett: Stocks Will Outperform Gold and Bonds .. and They're Safer 'By Far'
- Steelers' Antonio Brown Spends Super Bowl Week with Twitter Fan Turned BFF
- Investor Optimism At Highest In One Year: Survey
- Markets Get Greece Deal, So Where's the Big Rally?
- How to Get Your Name on the Bathroom Wall 4-EVER
- Indonesia Unexpectedly Cuts Rate to Seek Growth
- Kodak to Stop Making Cameras to Cut Costs
- Robo-Deal Is All About Lowering Mortgage Principal
- The Euro Still Has Room to Rise: Strategist
- Greeks Burn German Flags: Do They Have a Point?
- Victor Cruz ‘Understands’ Gisele's Super Bowl Frustrations
- Tamminen: The United States of India
- Unusual Volume: Taleo Jumps After Oracle's $1.9 Billion Offer
- Warren Buffett: Stocks Will Outperform Gold and Bonds .. and They're Safer 'By Far'
- So Now You Can’t Give Microsoft Away?
- Robo-Deal Is All About Lowering Mortgage Principal
- Groupon Needs More Disclosure: Analyst
- CEO to CEO: Taking a Job at a Startup vs. a Public Company
- Farr: Money, Jobs and Politics — We're Still in a State of Risk
- Markets Finally Get Greek Deal —So Where's the Rally?
- 'Mortgage Deal from Hell' Hurts Sound Borrowers: Bove
- Fidelity: 401(k) Balances Little Changed Over 2011
- Are Young American Workers a 'Lost Generation'?
- Westminster’s Most Successful Dog Breeds
- Greek Political Leaders Agree On Austerity Reforms
- Robo-Deal Is All About Lowering Mortgage Principal
- Fed Fines Banks $766 Million Over Mortgage Practices
- Spent Keurig K-Cups Filling Up US Landfills
RSS FEED
Pharma's Market
Text Size 
Roche To Genentech: Deal Or No Deal?
 |
The Swiss drug company is now offering 93 bucks a share for the 44 percent of DNA it doesn't already own. That's up from $86.50, which was down from the original bid of $89. Interestingly, Roche made the move on a Friday evening in Switzerland, in the middle of the trading day here in the States.
Roche, in the role of Howie Mandel who is a proxy for "the banker", is essentially trying to get Genentech shareholders to throw in the towel and take the $93 and go home. But there's still one briefcase left to be opened. It contains the results of the big study of Genentech's Avastin on earlier stage colon cancer. Analysts say if the drug works that it could add several billion dollars a year in revenue and send DNA [DNA
Loading...
()
] shares to around $100 and maybe even out of Roche's reach.
Clearly, Roche is trying to get this deal done before the results come out and it's counting on nervous shareholders, who might also need the cash right now in today's stock market, to take the bait. I think a key statement in the Roche release is Chairman Franz Humer's quote, "Based on conversations with Genentech shareholders, we believe there is a strong sentiment to bring this process to a conclusion."
But Genentech has already put out its own press release urging shareholders to leave it alone. The company says the three members of its board who make up the special committee assigned to deal with Roche will review the latest offer "promptly" and then explain its position "in detail" in a regulatory filing.
Game on.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
